EVFM - ネオセティクス (Evofem Biosciences Inc.) ネオセティクス

 EVFMのチャート


 EVFMの企業情報

symbol EVFM
会社名 Evofem Biosciences Inc (ネオセティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 医薬品   医療関連(Health Care)
概要 事業概要 Evofem Biosciences Inc formerly Neothetics Inc. is a clinical-stage specialty pharmaceutical company which develops therapeutics. The Company focuses on localized fat reduction and body contouring. It focuses on the development of LIPO-202 for the reduction of central abdominal bulging due to subcutaneous fat in non-obese patients. LIPO-202 is an injectable formulation of the long-acting Beta2-adrenergic receptor agonist and salmeterol xinafoate which is an active ingredient in the United States Food and Drug Administration inhaled products such as SEREVENT DISKUS ADVAIR HFA and ADVAIR DISKUS. The Company is developing a product candidate LIPO-102 an injectable form of a combination of salmeterol xinafoate and fluticasone propionate. LIPO-102 is indicated for the treatment of the orphan indication of symptomatic exophthalmos or protrusion of the eye from the orbit associated with thyroid-related eye disease caused by the expansion of fat and muscle behind the eye.   ネオセティクスは、米国の製薬会社。審美的な市場のための治療法の開発に従事。局所的な脂肪の減少と体の輪郭に焦点をあて製品の研究開発を行う。非肥満患者の皮下脂肪による中央腹部隆起の縮小のため臨床向けの治療法を開発し、臨床段階の医薬品として、LIPO-202およびLIPO-102を提供する。   Evofem Biosciences, Inc., is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (STIs). The Company's first commercial product, Phexxi® (lactic acid, citric acid and potassium bitartrate), is the first and only hormone-free, prescription vaginal gel approved in the United States for the prevention of pregnancy. The Company is evaluating EVO100 in a Phase 3 clinical trial, 'EVOGUARD,' for the prevention of urogenital Chlamydia trachomatis and Neisseria gonorrhoeae infection in women.
本社所在地 12400 High Bluff Drive Suite 600 San Diego CA 92130 USA
代表者氏名 Saundra Pelletier Saundra Pelletier
代表者役職名 Chief Executive Officer
電話番号 +1 858-550-1900
設立年月日 39114
市場名 NASDAQ Small Cap
ipoyear 2014年
従業員数
url www.evofem.com
nasdaq_url https://www.nasdaq.com/symbol/evfm
adr_tso
EBITDA EBITDA(百万ドル) -48.26041
終値(lastsale) 3.98
時価総額(marketcap) 102702407.5
時価総額 時価総額(百万ドル) 100.63800
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 77.85000
当期純利益 当期純利益(百万ドル) -96.53205
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Evofem Biosciences Inc revenues was not reported. Net loss applicable to common stockholders increased from $13.6M to $92.4M. Higher net loss reflects Loss on issuance of Invesco Warrants increase from $0K to $47.9M (expense) Research and development increase of 97% to $12M (expense) General and administrative increase of 73% to $9M (expense).

 EVFMのテクニカル分析


 EVFMのニュース

   The Daily Biotech Pulse: Vir-GlaxoSmithKline COVID-19 Antibody Treatment Approved, Zosano Spikes On Long-Term Migraine Drug Data, Decision Day For Eton, 2 IPOs  2021/05/27 12:23:08 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 26) I-Mab (NASDAQ: IMAB ) Nuvation Bio Inc. (NYSE: NUVB ) PDS Biotechnology Corporation (NASDAQ: PDSB ) Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS ) PLx Pharma Inc. (NASDAQ: PLXP ) West Pharmaceutical Services, Inc. (NYSE: WST ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows May 26) Assembly Biosciences, Inc. (NASDAQ: ASMB ) Axcella Health Inc. (NASDAQ: AXLA ) Black Diamond Therapeutics, Inc. (NASDAQ: BDTX ) Bolt Biotherapeutics, Inc. (NASDAQ: BOLT ) Coherus BioSciences, Inc. (NASDAQ: CHRS ) Evofem Biosciences, Inc. (NASDAQ: EVFM ) Impel NeuroPharma, Inc. (NASDAQ: IMPL ) IMV Inc. (NASDAQ: IMV ) Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT ) Ionis Pharmaceuticals, Inc. (NASDAQ: IONS ) Kiniksa Pharmaceuticals, Ltd. (NASDAQ: KNSA ) Larimar Therapeutics, Inc. (NASDAQ: LRMR ) ( reacted to a clinical hold imposed on Phase 1 study of CTI-1601 in Friedreich ataxia) Spruce Biosciences, Inc. (NASDAQ: SPRB ) Travere Therapeutics, Inc. (NASDAQ: TVTX ) (flagged a delay in regulatory filing for drug to treat kidney scarring) Viking Therapeutics, Inc. (NASDAQ: VKTX ) Stocks In Focus Vir-GlaxoSmithKline's Antibody Treatment Approved For Mild-To-Moderate COVID-19 GlaxoSmithKline plc (NYSE: GSK ) and Vir Biotechnology, Inc. (NASDAQ: VIR ) said the FDA granted an emergency use authorization for sotrovimab, an investigational single-dose monoclonal antibody, for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients12 years of age and older weighing at least 40 kg who have tested positive for SARS-CoV-2 and who are at high risk for progression to severe COVID-19, including hospitalization or death.
   Thinking about buying stock in Applied DNA Sciences, Sundial Growers, New Oriental Education, BlackBerry, or Evofem Biosciences?  2021/05/26 14:26:00 Benzinga
NEW YORK , May 26, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for APDN, SNDL, EDU, BB, and EVFM. Full story available on Benzinga.com
   Dividend Increases: May 15-21, 2021  2021/05/26 13:30:00 Seeking Alpha
   Evofem Biosciences stock tumbles toward a record low, after public stock offering prices at 25% discount  2021/03/25 12:24:40 MarketWatch
Shares of Evofem Biosciences Inc. undefined tumbled 24.9% toward a record low in premarket trading Thursday, after the biopharmaceutical company focused on…
   Evofem Biosciences' DTC Campaign "Get Phexxi" Delivers Strong Initial Impact  2021/03/17 12:00:00 PR Newswire
SAN DIEGO, March 17, 2021 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced that "Get Phexxi," its national direct-to-consumer (DTC) campaign aimed at broadening awareness of its non-hormonal, on-demand birth control method, Phexxi® (lactic acid, citric acid and…
   Evofem Biosciences Announces Publication in American Journal of Obstetrics and Gynecology of AMPREVENCE Study of EVO100 for Chlamydia and Gonorrhea Prevention  2021/03/16 12:00:00 PR Newswire
SAN DIEGO, March 16, 2021 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced publication of the pivotal manuscript from the AMPREVENCE clinical trial in the highly respected American Journal of Obstetrics and Gynecology (AJOG). This double-blinded,…
   31 Stocks Moving in Wednesday's Pre-Market Session  2021/03/10 12:19:45 Benzinga
Gainers MediciNova, Inc. (NASDAQ: MNOV ) shares rose 79.6% to $10.20 in pre-market trading after the biopharmaceutical company announced a partnership with the Biomedical Advanced Research and Development Authority (BARDA) to repurpose MN-166 (ibudilast) as a potential medical countermeasure against lung damage induced by chlorine gas. Exela Technologies, Inc. (NASDAQ: XELA ) rose 72.9% to $7.97 in pre-market trading. Exela Technologies shares jumped 179% on Tuesday after the company said it won a 10-year, $90-million contract delivering data transformation solutions for a major US insurer. Obalon Therapeutics, Inc. (NASDAQ: OBLN ) rose 50% to $5.31 in pre-market trading after climbing 18% on Tuesday. Atossa Therapeutics, Inc. (NASDAQ: ATOS ) shares rose 40.3% to $3.48 in pre-market trading after gaining over 16% on Tuesday. Atossa Therapeutics, last month, announced final results from its Phase 1 study evaluating AT-301 administered by nasal spray. AT-301 is being developed for at-home use for patients recently diagnosed with COVID-19..
   Evofem Biosciences (NASDAQ:EVFM) Releases Earnings Results  2021/03/06 14:56:50 Transcript Daily
Evofem Biosciences (NASDAQ:EVFM) posted its quarterly earnings results on Wednesday. The biotechnology company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.14), MarketWatch Earnings reports. Shares of EVFM opened at $2.28 on Friday. Evofem Biosciences has a 12-month low of $1.91 and a 12-month high of $6.87. […]
   Evofem Biosciences stock tumbles toward a record low, after public stock offering prices at 25% discount  2021/03/25 12:24:40 MarketWatch
Shares of Evofem Biosciences Inc. undefined tumbled 24.9% toward a record low in premarket trading Thursday, after the biopharmaceutical company focused on…
   Evofem Biosciences' DTC Campaign "Get Phexxi" Delivers Strong Initial Impact  2021/03/17 12:00:00 PR Newswire
SAN DIEGO, March 17, 2021 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced that "Get Phexxi," its national direct-to-consumer (DTC) campaign aimed at broadening awareness of its non-hormonal, on-demand birth control method, Phexxi® (lactic acid, citric acid and…
   Evofem Biosciences Announces Publication in American Journal of Obstetrics and Gynecology of AMPREVENCE Study of EVO100 for Chlamydia and Gonorrhea Prevention  2021/03/16 12:00:00 PR Newswire
SAN DIEGO, March 16, 2021 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced publication of the pivotal manuscript from the AMPREVENCE clinical trial in the highly respected American Journal of Obstetrics and Gynecology (AJOG). This double-blinded,…
   31 Stocks Moving in Wednesday's Pre-Market Session  2021/03/10 12:19:45 Benzinga
Gainers MediciNova, Inc. (NASDAQ: MNOV ) shares rose 79.6% to $10.20 in pre-market trading after the biopharmaceutical company announced a partnership with the Biomedical Advanced Research and Development Authority (BARDA) to repurpose MN-166 (ibudilast) as a potential medical countermeasure against lung damage induced by chlorine gas. Exela Technologies, Inc. (NASDAQ: XELA ) rose 72.9% to $7.97 in pre-market trading. Exela Technologies shares jumped 179% on Tuesday after the company said it won a 10-year, $90-million contract delivering data transformation solutions for a major US insurer. Obalon Therapeutics, Inc. (NASDAQ: OBLN ) rose 50% to $5.31 in pre-market trading after climbing 18% on Tuesday. Atossa Therapeutics, Inc. (NASDAQ: ATOS ) shares rose 40.3% to $3.48 in pre-market trading after gaining over 16% on Tuesday. Atossa Therapeutics, last month, announced final results from its Phase 1 study evaluating AT-301 administered by nasal spray. AT-301 is being developed for at-home use for patients recently diagnosed with COVID-19..
   Evofem Biosciences (NASDAQ:EVFM) Releases Earnings Results  2021/03/06 14:56:50 Transcript Daily
Evofem Biosciences (NASDAQ:EVFM) posted its quarterly earnings results on Wednesday. The biotechnology company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.14), MarketWatch Earnings reports. Shares of EVFM opened at $2.28 on Friday. Evofem Biosciences has a 12-month low of $1.91 and a 12-month high of $6.87. […]

 関連キーワード  (医薬品 米国株 ネオセティクス EVFM Evofem Biosciences Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)